Second, along the same line, the observation that combination treatment of cultured CML cells with Imatinib and TGF-β produced better growth inhibitory and apoptotic effects suggests a possible combination therapy involving TKI and TGF-β agonists. Here, TGFB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.